

Special Issue

Therapy in Gastrointestinal Oncology

Message from the Guest Editors

Our understanding of the biology of cancer has grown rapidly over the last decade, leading to advances in new types of targeted therapies and novel therapeutic approaches. This Special Issue will discuss recent advances in minimally invasive treatment for GI oncology; endoscopic therapy for early GI cancers; surgical management (including techniques and considerations for minimally invasive approaches); and innovations in neoadjuvant and adjuvant chemotherapy, immunotherapy, and radiation treatment for GI cancers. This Special Issue will also discuss the roles of the novel therapies, including rational and structure-based drug design, that are currently being pursued in the clinical setting and hold the promise of improving the clinical outcome of these conditions.

Guest Editors

Dr. Saowanee Ngamruengphong

Assoc. Prof. Dr. Fabian M. Johnston

Assoc. Prof. Dr. Lei Zheng

Deadline for manuscript submissions

closed (31 December 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/72466

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)